Phase IIIb TALON RCT in 734 patients with neovascular AMD on treat-and-extend: at week 64, 28.4% on brolucizumab vs 12.2% on aflibercept had a 16-week interval with no disease activity; vision gains were similar, but serious ocular AEs were 2.7% vs 0.8%.
RCTn = 734
Regillo et al. TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration